Mora-Hernández S, Sosa-Caballero A, Alamilla-Lugo L, Velázquez-Chávez FJ

Language: Spanish
References: 18
Page: 18-21
PDF size: 185.51 Kb.

ABSTRACT

Background: Survival and recurrence rates in well-differentiated thyroid carcinoma (WTC) are influenced by several factors, that grouped together constitute prognostic scales that aid in the establishment of management plans for this neoplasm. Objective: To apply different prognostic scales to a large number of patients with WTC, searching for concordances and discrepancies between them. Methods: We reviewed the clinical records of 592 patients with WTC between November 2008 and February 2009. Different prognostic scales were applied using this information. Descriptive statistics as well and Spearman’s correlation and linear rate Kappa statistic were performed. Results: Mean patient age was 44 years, 90.4% females, with a mean follow up of 5.6 years. Papillary carcinoma was present in 96.6%; mean tumor size was 2.1 cm and invasion of the capsule was found in 55.1%; regional lymph nodes metastasis was discovered in 16.9% whereas only 7 patients showed evidence of distant metastasis. A high-risk category was assigned to 30% using the TNMP scale, 16.8% using the EORTC scale, 57% using the Chicago scale, 4.5% and 10.5% in women and men, respectively, using the Noguchi scale, 20% using the AMES scale, 6.6% using the MACIS scale and 72.2% using the classification of the SMNE. Conclusions: Whereas some grading systems classify patients as high risk others do not, emphasizing the need to individualize patient management.

REFERENCES

1. Byar DP, Green SB, Dor P, Williams ED, Colon J, Van Gilse HA, Mayer M, Sylvester RJ, Van Glabbeke M. A prognostic index for thyroid carcinoma. A study of EORTC Thyroid Cancer Cooperative Group. Eur J Cancer 1979; 15: 1033-1041.

2. Duntas L, Grab-Duntas BM. Risk and prognostic factors for differentiated thyroid cancer. Hell J Nucl Med 2006; 9: 156-162.

3. Sywak M, Pasieka JL, Ogilvie T. A review of thyroid cancer with intermediate differentiation. J Surg Oncol 2004; 86: 44-54.

4. Leung AK, Chow SM, Law SC. Clinical features and outcome of the tall cell variant of papillary thyroid carcinoma. Laryngoscope 2008; 118: 32-38.

5. Jukkola A, Bloigu R, Ebeling T, Salmela P, Blanco G. Prognostic factors in differentiated thyroid carcinomas and their implications for current staging classifications. Endocr Relat Cancer 2004; 11: 571-579.

6. Hung-Hin BL, Chung-Yau L, Wai-Fan C, King-Yin L, Koon-Yat W. Staging systems for papillary thyroid carcinoma: A review and comparison. Ann Surg 2007; 245: 366-378.

7. Marković IZ, Džodić RR, Inić M, Juškić M, Jokić N, Žegarac M. Prognostic factors in differentiated thyroid carcinoma. Archive of Oncology 2003; 11: 181-182.

8. DeGroot LJ, Kaplan EL, McCormick M, Strauss FH. Natural history, treatment, and course of papillary thyroid carcinoma. J Clin Endocrinol Metab 1990; 71: 414-424.

9. Noguchi S, Murakami N, Kawamoto H. Classification of papillary cancer of the thyroid based on prognosis. World J Surg 1994; 18: 552-558.

10. Haigh PI, Urbach DR, Rotstein LE. AMES prognostic index and extent of thyroidectomy for well-differentiated thyroid cancer in the United States. Surgery 2004; 136: 609-616.

11. Paiseka JL, Zedenius J, Auer G, Grimelius L, Hoog A, Lundell G et al. The addition of nuclear DNA content to the AMES risk-group classification for papillary thyroid cancer. Surgery 1992; 112: 1154-1160.

12. Hay ID, Bergstralh EJ, Goellner JR, Ebersold JR, Grant CS. Predicting outcome in papillary thyroid carcinoma: development of reliable prognostic scoring system in a cohort of 1,779 patients surgically treated at one institution during 1940 through 1989. Surgery 1993; 114: 1050-1057.

13. Grupo de Consenso en Tiroides. Guía Clínica para el Diagnóstico y Tratamiento del Cáncer Diferenciado de Tiroides En: www.endocrinologia.org.mx/v2/paginas/concenso.php

14. Bolaños GMF, Durón HH, González OM, Vázquez CG, Ramos SF. Comparison of three prognostic indexes in differentiated thyroid cancer. Rev Invest Clin 1999; 51: 285-288.

15. Bolaños-Gil-de-Montes F, González-Ortiz M, Vázquez-Camacho G, Ramos- Solano F. Usefulness of four prognostic indices in differentiated thyroid cancer. Rev Invest Clin 2004; 56: 304-308.

16. Rodríguez-Cuevas S, Labastida-Almedaro S, Briceño-Ancona N, González-Rodríguez D. Reintervención para completar el tratamiento quirúrgico en cáncer de tiroides. Indicaciones y hallazgos histopatológicos. Gac Méd Méx 1998; 134: 677-683.

17. Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA 2006; 295: 2164-2167.

18. Yildirim E. A model for predicting outcomes in patients with differentiated thyroid cancer and model performance in comparison with other classification systems. J Am Coll Surg 2005; 200: 378-392.